Antonio Gualberto - Kura Oncology Chief Medical Officer
| KURA Stock | USD 17.99 0.60 3.23% |
Executive
Dr. Antonio Gualberto, M.D., Ph.D., is the Head of Development and Chief Medical Officer of Kura Oncology Inc., He has served as our Head of Development and Chief Medical Officer since January 2018 and Chief Medical Officer since the Merger in March 2015. Dr. Gualberto cofounded Prior Kura in August 2014 and served as the Chief Medical Officer of Prior Kura from October 2014 until the Upstream Merger in March 2015. From June 2012 to September 2014, Dr. Gualberto served as the head of the global clinical development center for oncology at EMD Serono, Inc., the biopharmaceutical subsidiary in the United States of Merck KGaA, Darmstadt, Germany, a global pharmaceutical and chemical group. Prior to this, from September 2010 to April 2012, Dr. Gualberto served as a group head of clinical research for the Takeda Oncology Company, a privatelyheld biopharmaceutical company. From October 1999 to August 2010, Dr. Gualberto served in varying roles at Pfizer, Inc., a publiclyheld pharmaceutical company, including Senior Director, Clinical Development and Medical Affairs, and Global Clinical Leader. He has also held several academic positions including, from October 2008 to June 2012, an adjunct appointment of associate professor of pathology and laboratory medicine at The Warren Alpert Medical School of Brown University since 2018.
| Age | 53 |
| Tenure | 6 years |
| Professional Marks | Ph.D |
| Address | 12730 High Bluff Drive, San Diego, CA, United States, 92130 |
| Phone | 858 500 8800 |
| Web | https://kuraoncology.com |
Kura Oncology Management Efficiency
The company has return on total asset (ROA) of (0.229) % which means that it has lost $0.229 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3734) %, meaning that it created substantial loss on money invested by shareholders. Kura Oncology's management efficiency ratios could be used to measure how well Kura Oncology manages its routine affairs as well as how well it operates its assets and liabilities. As of April 18, 2024, Return On Tangible Assets is expected to decline to -0.36. The current year's Return On Capital Employed is expected to grow to -0.38. At present, Kura Oncology's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 454.1 M, whereas Return On Tangible Assets are forecasted to decline to (0.36).Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Anne Lapointe | Provident Bancorp | N/A | |
| Dawn FitzgeraldWilliams | Home Federal Bancorp | N/A | |
| Jean Kim | Provident Bancorp | 50 | |
| Donna Lewis | Home Federal Bancorp | 61 | |
| Kevin Barton | Provident Bancorp | N/A | |
| Kenneth Fisher | Provident Bancorp | N/A | |
| Alejandro Miranda | Betterware De Mexico | N/A | |
| DeNell Mitchell | Home Federal Bancorp | 68 | |
| Pilar Sanchez | Betterware De Mexico | N/A | |
| Carlos Doormann | Betterware De Mexico | 53 | |
| Janine Jakubauskas | Provident Bancorp | N/A | |
| Juan Hernandez | Betterware De Mexico | N/A | |
| Kimberly Scholtz | Provident Bancorp | N/A | |
| Mauricio Alvarez | Betterware De Mexico | 54 | |
| Joseph Kenney | Provident Bancorp | N/A | |
| John Batson | Home Federal Bancorp | N/A | |
| Reynaldo VizcarraMendez | Betterware De Mexico | 58 | |
| Denise Gallant | Provident Bancorp | N/A | |
Management Performance
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.23 |
Kura Oncology Leadership Team
Elected by the shareholders, the Kura Oncology's board of directors comprises two types of representatives: Kura Oncology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kura. The board's role is to monitor Kura Oncology's management team and ensure that shareholders' interests are well served. Kura Oncology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kura Oncology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Steven Stein, Director | ||
| Mollie MD, Executive Development | ||
| Francis Burrows, Senior Research | ||
| Roger Bakale, Clinical CMC | ||
| Thomas Malley, Director | ||
| Marc MD, Advisor | ||
| Mary Szela, Director | ||
| John Farnam, COO | ||
| Thomas Doyle, Principal Accounting | ||
| Esq JD, Chief Sec | ||
| MS MBA, Chief Officer | ||
| Kirsten Flowers, Chief Officer | ||
| Pingda Ren, Sr. VP of Chemistry and Pharmaceutical Sciences | ||
| Heidi Henson, CFO, Secretary | ||
| Troy Wilson, Chairman of the Board and Presidentident, CEO, Co-Founder | ||
| Kathleen Ford, Chief Officer | ||
| JD Esq, Chief Secretary | ||
| Stephen MD, Chief Officer | ||
| Faheem Hasnain, Independent Director | ||
| Annette North, Senior Vice President General Counsel | ||
| Liu Yi, Co-Founder, Chief Scientific Officer | ||
| Troy JD, CEO, Chairman | ||
| Antonio Gualberto, Chief Medical Officer | ||
| Marc Grasso, CFO and Chief Business Officer | ||
| Pete Spain, Executive Communications | ||
| Robert Hoffman, Independent Director | ||
| Maureen MBA, VP Management |
Kura Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kura Oncology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.23 | ||||
| Current Valuation | 1.01 B | ||||
| Shares Outstanding | 76.18 M | ||||
| Shares Owned By Insiders | 1.75 % | ||||
| Shares Owned By Institutions | 98.25 % | ||||
| Number Of Shares Shorted | 10.41 M | ||||
| Price To Earning | (9.03) X | ||||
| Price To Book | 3.73 X | ||||
| EBITDA | (164.96 M) |
Kura Oncology Investors Sentiment
The influence of Kura Oncology's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Kura. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Kura Oncology's public news can be used to forecast risks associated with an investment in Kura. The trend in average sentiment can be used to explain how an investor holding Kura can time the market purely based on public headlines and social activities around Kura Oncology. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Kura Oncology's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Kura Oncology's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Kura Oncology's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Kura Oncology.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Kura Oncology in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Kura Oncology's short interest history, or implied volatility extrapolated from Kura Oncology options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kura Oncology. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Complementary Tools for Kura Stock analysis
When running Kura Oncology's price analysis, check to measure Kura Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kura Oncology is operating at the current time. Most of Kura Oncology's value examination focuses on studying past and present price action to predict the probability of Kura Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kura Oncology's price. Additionally, you may evaluate how the addition of Kura Oncology to your portfolios can decrease your overall portfolio volatility.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |
Is Kura Oncology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kura Oncology. If investors know Kura will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kura Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.08) | Return On Assets (0.23) | Return On Equity (0.37) |
The market value of Kura Oncology is measured differently than its book value, which is the value of Kura that is recorded on the company's balance sheet. Investors also form their own opinion of Kura Oncology's value that differs from its market value or its book value, called intrinsic value, which is Kura Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kura Oncology's market value can be influenced by many factors that don't directly affect Kura Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kura Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kura Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kura Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.